Impact of HBAIC in type 2 diabetes mellitus in Mexico:: Simulation analysis, a pharmacoeconomic perspective

被引：0
|
作者：
Castañeda, R. C. L. [1 ]
Sil, M. J. S. A. [1 ]
Acevedo, G. A. R. [1 ]
Manterola, S. O. M. C. [2 ]
Ramirez, J. R. [3 ]
Rios, L. R. N. [3 ]
Romero, S. R. [4 ]
Barquera, S. B. [5 ]
机构：
[1] Hosp Carlos Mc Gregor Sanchez Navarro, IMSS, Mexico City, DF, Mexico
[2] Sanofi Aventis Mexico, Mexico City, DF, Mexico
[3] Natl Inst Cardiol Ignacio Chavez, Mexico City, DF, Mexico
[4] Inst Mexicano Seguro Social, Zona Poniente, Toluca, Mexico
[5] Natl Inst Publ Hlth, Cuernavaca, Morelos, Mexico
来源：
VALUE IN HEALTH | 2007年 / 10卷 / 06期
关键词：
D O I：
10.1016/S1098-3015(10)64987-X
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A266 / A266
页数：1
相关论文
共 50 条
  • [21] Dietary Inflammatory Index and Type 2 Diabetes Mellitus in Adults: The Diabetes Mellitus Survey of Mexico City
    Denova-Gutierrez, Edgar
    Munoz-Aguirre, Paloma
    Shivappa, Nitin
    Hebert, James R.
    Tolentino-Mayo, Lizbeth
    Batis, Carolina
    Barquera, Simon
    NUTRIENTS, 2018, 10 (04)
  • [22] BUDGET IMPACT ANALYSIS OF DAPAGLIFLOZIN FOR THE TREATMENT OF TYPE 2 DIABETES MELLITUS IN CHINA
    Liu, C.
    Xie, S.
    Wu, J.
    VALUE IN HEALTH, 2018, 21 : S37 - S37
  • [23] Achieving target HbAIC in studies with inhaled insulin in Type 2 diabetes
    Bergenstal, M
    DIABETOLOGIA, 2004, 47 : A312 - A312
  • [24] Cost-effectiveness analysis of alogliptin in type 2 diabetes mellitus: a payer perspective
    Patel, Dhruv
    Tai, Bik-Wai Bilvick
    Law, Anandi
    PHARMACOTHERAPY, 2013, 33 (10): : E268 - E268
  • [25] Pharmacoeconomic assessment of type 2 diabetes mellitus care on the base of Endocrinology Research Centre, Moscow
    Dedov, I. I.
    Shestakova, M. V.
    Tarasov, E. V.
    Shestakova, E. A.
    DIABETES MELLITUS, 2012, 15 (03): : 101 - 109
  • [26] Pharmacoepidemiological and pharmacoeconomic analyses of the utilization of hypoglycaemic drugs in patients with type 2 diabetes mellitus in Moscow
    Kalashnikova, M. F.
    Belousov, D. Y.
    Suntsov, Y., I
    Kantemirova, M. A.
    Dedov, I. I.
    DIABETES MELLITUS, 2015, 18 (02): : 32 - 46
  • [27] GlipizideA Review of the Pharmacoeconomic Implications of the Extended-Release Formulation in Type 2 Diabetes Mellitus
    Rachel H. Foster
    Greg L. Plosker
    PharmacoEconomics, 2000, 18 : 289 - 306
  • [28] Glipizide - A review of the pharmacoeconomic implications of the extended-release formulation in Type 2 diabetes mellitus
    Foster, RH
    Plosker, GL
    PHARMACOECONOMICS, 2000, 18 (03) : 289 - 306
  • [29] The impact of type 2 diabetes mellitus on daily functioning
    de Grauw, WJC
    van de Lisdonk, EH
    Behr, RRA
    van Gerwen, WHEM
    van den Hoogen, HJM
    van Weel, C
    FAMILY PRACTICE, 1999, 16 (02) : 133 - 139
  • [30] IMPACT OF STRESS ON TYPE 2 DIABETES MELLITUS MANAGEMENT
    Vasanth, R.
    Ganesh, Aparna
    Shanker, R.
    PSYCHIATRIA DANUBINA, 2017, 29 : S416 - S421
12345